Skip to content

ETHERNA IMMUNOTHERAPIES

Active
Public limited companyfounded 2013active for 13 yearsGalileilaan 19, 2845 Niel, BelgiumKBO/BCE: BE 0502.703.389
Summary

The computed 12-month bankruptcy probability of ETHERNA IMMUNOTHERAPIES is 1.7% (moderate). The 2025 annual accounts show negative equity (-€3.9m) and a net result of -€4.3m. The figures fluctuate too strongly year-on-year for a reliable trend projection. Its solvency ranks better than 7% of 239 sector peers (NACE 72, financial year 2025). The company has been active since 2013 and the Belgian Official Gazette contains no insolvency or warning signals.

Overview

Activity
Other research and development on natural sciences
NACE 72109
3rd largest company by total assets in Niel, Professional and technical services sector3 sites
Size
€8.8mturnover 2025
Staff
52.1 FTE
Equity
-€3.9m
Loss
-€4.3m
Financial health
54 Fair Checked score 2025
Bankruptcy probabilitywithin 12 months
1.7%
Structure
Parent
PROGRESS PHARMA · 100%
Holdings
4
Accounts 63 days early5 of 34 deeds read
Why 54raises riskNegative equity -€3.9mLoss of €4.3m, the second in a row (financial year 2025)Founded in 2013lowers riskSize: turnover €8.8m, 52.1 FTE, total assets €12.8mShow the evidence

Checked score

Score 2025
54 / 100
Fair
Probability in this band: 1.5% to 4.2%
Financially better than 24% of its sector peers (NACE 72, medium-sized)
Financial strength · tick = 2024
Weak
Solvency 0-27
equity -30.6% of total assets
Liquidity 37-22
short-term debt 68.1% · cash 19.0%
Profitability 53-3
return on assets -33.5%
Bankruptcy probability, 12 months
1.7% Moderate
0%0.5%1.5%4%10%≥ 25%

About 2 in 100 comparable companies go bankrupt within 12 months (an estimate).

Sector median 0.1% (47 companies, NACE 72, medium-sized)
Last 24 months 11-2024: 0.4% 12-2024: 0.4%● unchanged vs 11-2024 01-2025: 0.4%● unchanged vs 12-2024 02-2025: 0.3%▼ -0.1 percentage points vs 01-2025lowest value 03-2025: 0.3%● unchanged vs 02-2025lowest value 04-2025: 0.4%▲ +0.1 percentage points vs 03-2025 05-2025: 0.4%● unchanged vs 04-2025 06-2025: 0.7%▲ +0.3 percentage points vs 05-2025 07-2025: 0.7%● unchanged vs 06-2025 08-2025: 0.7%● unchanged vs 07-2025 09-2025: 0.7%● unchanged vs 08-2025 10-2025: 0.7%● unchanged vs 09-2025 11-2025: 0.7%● unchanged vs 10-2025 12-2025: 0.7%● unchanged vs 11-2025 01-2026: 0.7%● unchanged vs 12-2025 02-2026: 0.7%● unchanged vs 01-2026 03-2026: 0.7%● unchanged vs 02-2026 04-2026: 0.7%● unchanged vs 03-2026 05-2026: 0.7%● unchanged vs 04-2026 06-2026: 0.7%● unchanged vs 05-2026 07-2026: 1.7%▲ +1.0 percentage point vs 06-2026highest value 08-2026: 1.7%● unchanged vs 07-2026highest value 09-2026: 1.7%● unchanged vs 08-2026highest value 10-2026: 1.7%● unchanged vs 09-2026highest value
No credit on open account
Liquidity insufficient (current ratio 0.77, compared with 1.84 in 2024, below 1; short-term debt: 68.1% and cash: 19% of total assets), and equity is negative.
How it is calculated

The band follows from the bankruptcy probability, on a scale where 10 more points roughly halve it:

75-100 Excellent under 0.55%
60-74 Healthy 0.55% to 1.5%
45-59 Fair 1.5% to 4.2%
25-44 Weak 4.2% to 15.0%
0-24 Critical over 15.0%

Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 72, medium-sized): better than 6% on solvency, 38% on liquidity, 38% on profitability and 12% on growth.

The bankruptcy probability was computed on 18-10-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.

Some facts cap the score, however low the probability. Negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late hold it at Fair at most (59); two missing filings, at Weak (44). An ongoing judicial reorganisation or the company's end (bankruptcy, dissolution, liquidation) holds it at Critical at most (24).

Credit check for your own amount and term

Show the recommended maximum and see how the verdict changes with amount, term and advance.

Signals

Six signals.
lowers riskraises riskneutral
raises risk · Negative equity -€3.9m
NBB · annual accounts
raises risk · Loss of €4.3m, the second in a row (financial year 2025)
NBB · annual accounts
lowers risk · Size: turnover €8.8m, 52.1 FTE, total assets €12.8m
Companies of this size fail less often; how much that weighs depends on the rest of its profile.
NBB · annual accounts
raises risk · Founded in 2013
Companies of this age fail more often than older ones; how much that weighs depends on the rest of its profile.
KBO
raises risk · Negative equity
The 2025 annual accounts show negative equity and a net loss.
NBB · annual accounts 2025
Equity per financial year
19202122232425
2019 to 2025 · latest year -€3.9m
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 29-05-2026, 63 days ahead of the deadline.
NBB · 10 filings
Deviation from the deadline
2025
63 days early
2024
65 days early
2023
85 days early
2022
83 days early
2021
69 days early
2020
73 days early
2019
16 days early
← before the deadline after the deadline →
tick = median of all Belgian filingsring = median in the sector

This company filed its last 7 accounts on average 65 days before the deadline; the sector median (NACE 72) for financial year 2024 is 13 days before the deadline, and 33% of those companies filed late.

Searched, nothing found (2)
neutral · Next filing not due yet
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. The company usually files around 23 May (5 of the last 5 filed years within 30 days of that day).
Companies Code · seven months
Where today falls in the filing period
18-10-2026 today31-12-2026 year end31-07-2027 deadline
neutral · No strike-offs in the KBO publications
Searched since 2021.
KBO publications · our coverage
  1. Permanent representatives: Tobias Wilms and Kenneth…Gazette deed
  2. Annual accounts filedfinancial year 2025 · full…
  3. Annual accounts filedfinancial year 2024 · full…

Key points

  • Risk: Negative equityfinancial year 2025: debts exceed assets -€3.9m View
  • Risk: 7 loss-making years in a rowloss financial year 2025 -€4.3m View
  • Caution: Among the weakest 5% on equitysector median €1.3m · 238 companies -€3.9m View
  • Positive: Filed on time since financial year 2018accounts within the deadline every year 8 years View
  • Controlled by PROGRESS PHARMAthe company in turn controls 3 companies 100% View
  • Positive: Result rose in 2025from -€6.6m to -€4.3m ▲ 35.5% View
  • EU research moneyEU contribution €12.5m View

By topic

Financials

Financial year
2025
Turnover
€8.8m
Loss
-€4.3m
Solvency
-30.6%
Turnover▼ 21.7%
Net result
20222025
Go to Financials

Timeline

Events
21
Since
2014
Next accounts
by 31-07-2027
  1. 18-03-2025Capital & shares · Amendment of the…
  2. 05-11-2024Reappointment: PwC Bedrijfsrevisoren BV (statutory auditor)
  3. 25-06-2024Amendment of the articles · Miscellaneous
Go to Timeline

Company details

Sites
3
Legal form
Public limited company
Activity
Other research and development on natural sciencesNACE 72109
Founded
21-01-2013
Year ends
31-12
Peppol
Reachable for e-invoices
Go to Company details

Go further with this company

Your own company? See how customers, suppliers and banks see it and what to improve first.

Investigating this company? Keep it with today's facts in a case file.